Ephedrine: Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Navigation

DRUG NAME: Ephedrine

Therapeutic Class: Vasopressor
Subclass: Alpha- and beta-adrenergic agonist
Speciality: Anaesthesiology

Schedule (India): Schedule H
Route(s): Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Oral (limited use)
Formulations Available in India:
• Injection: 30 mg/mL, 50 mg/mL (as ephedrine hydrochloride)
• Oral tablet: 25 mg (limited availability; not generally marketed for systemic use in India)

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ Intraoperative Hypotension (especially during spinal/epidural anaesthesia)

Parameter	Recommendation
Starting dose	5–10 mg IV bolus
Titration	Repeat 5–10 mg IV every 3–4 minutes as needed based on blood pressure response
Usual maintenance dose	Titrated to blood pressure; cumulative dosing based on response
Maximum dose	50 mg total per anaesthetic procedure

Clinical Notes:
• Monitor blood pressure and heart rate closely during administration
• Preferred agent in obstetric anaesthesia for neuraxial block-induced hypotension, particularly when heart rate is low or borderline
• More effective than phenylephrine when bradycardia is present
• Ensure adequate volume status before initiating vasopressor therapy

Secondary Indications — Adults (Off-label, if any)

▶ Refractory Hypotension in ICU Settings — OFF-LABEL

Parameter	Recommendation
Starting dose	5–25 mg IV bolus
Titration	Repeat as needed based on haemodynamic response
Usual maintenance dose	Bolus dosing preferred; continuous infusion rarely used
Maximum dose	Titrate to effect; no defined upper limit
Duration	Short-term use during acute hypotensive episodes

• Specialist only
• Evidence basis: Indian ICU practice; used as adjunct vasopressor in catecholamine-resistant hypotension

▶ Narcolepsy (historic use) — OFF-LABEL

Parameter	Recommendation
Starting dose	25 mg oral 2–3 times daily
Titration	May increase to 50 mg 2–3 times daily based on response
Usual maintenance dose	25–50 mg oral 2–3 times daily
Maximum dose	150 mg/day

• Not routinely used; safer CNS stimulants are preferred alternatives
• Specialist only
• Evidence basis: Historic use; largely replaced by modafinil and other agents

PAEDIATRIC DOSING (Specialist Only)

Primary Indication

▶ Intraoperative Hypotension (perioperative support)

Parameter	Recommendation
Starting dose (IV bolus)	0.1–0.2 mg/kg/dose
Titration	Repeat every 5–10 minutes based on blood pressure and heart rate response
Usual maintenance dose	Based on haemodynamic response; bolus dosing preferred
Maximum dose	10 mg per single dose
Minimum age	No fixed lower age limit; use only under paediatric anaesthetist or intensivist supervision

Safety Monitoring:
• Continuous blood pressure and heart rate monitoring mandatory
• Avoid in patients with tachyarrhythmias
• Ensure adequate volume resuscitation prior to use

Secondary Indications — Paediatric Doses (Off-label, if any)

• Not routinely recommended for chronic use in paediatric population
• Oral use discouraged in children
• Use outside intraoperative hypotension management is restricted to monitored intensive care settings under specialist supervision

RENAL ADJUSTMENT

Renal Function	Recommendation
Mild to moderate impairment	No specific dose adjustment required
Severe impairment	Use with caution; reduced clearance may lead to drug accumulation

Monitoring: Blood pressure, heart rate, and signs of CNS stimulation should be closely monitored

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No dose adjustment required; use with caution
Moderate impairment	Use with caution; no specific dose adjustment
Severe impairment	Use with caution; hepatic metabolism may be impaired; monitor for prolonged duration of effect

CONTRAINDICATIONS

• Known hypersensitivity to ephedrine or related sympathomimetics
• Phaeochromocytoma
• Severe hypertension
• Closed-angle glaucoma
• Tachyarrhythmias (e.g., atrial fibrillation with rapid ventricular rate, ventricular tachycardia)
• Concurrent use of monoamine oxidase inhibitors (MAOIs)

CAUTIONS

• Ischaemic heart disease
• Diabetes mellitus
• Hyperthyroidism
• Prostatic hypertrophy (risk of urinary retention)
• Seizure disorders
• Volume-depleted states — correct hypovolaemia before use
• Elderly patients
• Repeated doses may cause tachyphylaxis (diminishing response)
• Risk of ventricular arrhythmias at high doses or in predisposed individuals
• Avoid concurrent use with other sympathomimetics

PREGNANCY

Consideration	Recommendation
Overall safety	Generally considered safe for short-term intraoperative use
When it may be used	Preferred agent for spinal/epidural anaesthesia-induced hypotension in obstetrics, particularly when maternal heart rate is low or borderline
Preferred alternatives	Phenylephrine may be preferred when heart rate is normal or elevated
Monitoring	Maternal heart rate, blood pressure; fetal heart rate monitoring

• Safe for short-term supervised use during obstetric anaesthesia

LACTATION

Consideration	Recommendation
Compatibility	Likely compatible with breastfeeding at perioperative doses
Drug levels in milk	No significant transfer expected with short-term perioperative use
Preferred alternatives	Oral/chronic use discouraged during lactation
Infant monitoring	Restlessness, poor feeding, irritability, weight gain if repeated maternal use

ELDERLY

Consideration	Recommendation
Starting dose	Lower end of dose range (5 mg IV bolus)
Titration	Slower titration preferred
Risks	Hypertension, tachyarrhythmias, agitation, urinary retention, CNS stimulation
Monitoring	Blood pressure, heart rate, cardiac rhythm, urinary output

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect / Mechanism	Recommendation
Monoamine oxidase inhibitors (MAOIs)	Risk of hypertensive crisis due to inhibited catecholamine breakdown	Contraindicated — avoid combination
Ergot alkaloids	Additive vasoconstriction; risk of severe peripheral ischaemia	Avoid combination
Other sympathomimetics (pseudoephedrine, phenylephrine, adrenaline)	Additive cardiovascular toxicity	Avoid or use with extreme caution
Tricyclic antidepressants	Potentiation of pressor effect	Avoid or monitor closely

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect / Mechanism	Recommendation
Beta-blockers	May reduce efficacy of ephedrine; paradoxical hypertension possible	Monitor blood pressure closely
Halothane and other halogenated anaesthetics	Sensitization of myocardium to catecholamine-induced arrhythmias	Avoid high doses of ephedrine
Antihypertensives	May blunt hypotensive effect of antihypertensives	May require dose adjustment of antihypertensives
Digoxin	Additive risk of arrhythmias	Monitor cardiac rhythm
Theophylline	Additive CNS and cardiovascular stimulation	Monitor for toxicity signs

COMMON ADVERSE EFFECTS

• Nausea
• Palpitations
• Hypertension
• Restlessness or insomnia
• Urinary retention (especially in elderly males)
• Headache
• Tremor

SERIOUS ADVERSE EFFECTS

Adverse Effect	Clinical Note
Arrhythmias (atrial or ventricular)	May require immediate discontinuation
Hypertensive crisis	Requires immediate management
Pulmonary oedema	Rare; may occur with overdose
Myocardial ischaemia	Monitor for chest pain in at-risk patients
CNS overstimulation or seizures	At high doses or with rapid IV bolus; requires hospitalisation

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Blood pressure, heart rate, ECG
During treatment	Continuous BP and HR monitoring during IV administration
Long-term	Not applicable — ephedrine is not intended for long-term use

BRANDS AVAILABLE IN INDIA

• Ephedrine Hydrochloride Injection (Neon Laboratories)
• Epasol Injection (Samarth Pharma)
• Ephetox Injection

Note: Oral formulations available in some OTC decongestant combinations but discouraged for systemic use

PRICE RANGE (INR)

• Ephedrine 30 mg/mL injection: ₹15–₹25 per ampoule
• Not included in NLEM
• Available under Schedule H in private sector supply
• Not under NPPA price control

CLINICAL PEARLS

• Preferred vasopressor for spinal anaesthesia-induced hypotension in obstetric settings, especially when maternal heart rate is low or borderline
• Less potent than phenylephrine but has positive chronotropic effect — useful when bradycardia accompanies hypotension
• Avoid cumulative doses exceeding 50 mg per procedure; tachyphylaxis and arrhythmia risk increase with repeated dosing
• Not suitable for long-term use as decongestant or CNS stimulant due to abuse potential and adverse effect profile
• Always verify absence of concurrent beta-blocker or sympathomimetic use before IV administration
• Use slow titration in elderly patients or those with coronary artery disease

VERSION

RxIndia v1.0 — 19 Feb 2026

REFERENCES

• CDSCO
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• AIIMS Anaesthesia Protocols
• Indian Society of Anaesthesiologists (ISA) Guidelines
• API Textbook of Medicine
• Harrison’s Principles of Internal Medicine
• Indian ICU practice patterns (for off-label indications)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.